Mizuho Maintains Neutral on Apellis Pharmaceuticals, Lowers Price Target to $39
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Graig Suvannavejh has maintained a Neutral rating on Apellis Pharmaceuticals (NASDAQ:APLS) while lowering the price target from $42 to $39.
September 20, 2024 | 5:30 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Mizuho has maintained a Neutral rating on Apellis Pharmaceuticals and reduced the price target from $42 to $39, indicating a slightly less optimistic outlook.
The reduction in price target from $42 to $39 by Mizuho suggests a less optimistic view on Apellis Pharmaceuticals' short-term performance. This could lead to a negative sentiment among investors, potentially impacting the stock price negatively in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100